Smilax Laboratories Limited

VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow

ACTIVE PHARMA INGREDIENTS

62 All APIs, 2 USDMF, 9 CEP/COS, 2 JDMF, 9 EU WC, 2 KDMF, 4 NDC API, 58 Listed APIs

INTERMEDIATES

88 ALL Intermediates

88 ALL Intermediates

FINISHED DOSAGE FORMULATIONS

81 FDF Dossiers, 81 Listed Dossiers

INSPECTIONS & REGISTRATIONS

6 FDA, 3 EDQM, 1 WHO-GMP

Filters

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]

“We’re investing in next-gen CDMO & peptide building blocks infrastructure to support the evolving demands of complex therapies.”

This week, SpeakPharma interviews Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions (LMS). In this exclusive interview with PharmaCompass, Dr. Toumi discusses the evolving CDMO landscape, the shift toward complex therapies and growing peptide ecosystems along with LMS’s recent strategic investments in integrated CDMO and peptide building blocks infrastructure. As the industry convenes at DCAT Week, he highlights how LMS is positioning itself as a capability-driven CDMO partner for next-gen complex therapies.Dr. Toumi, The US has been taking several steps to reduce dependence on overseas pharmaceutical supply chains. How is Lupin Manufacturing Solutions (LMS) navigating these shifts?The framing of this debate as globalization versus reshoring misses what is actually happening. What we are seeing is a deliberate recalibration, a move from networks built purely for cost efficiency toward architectures that distribute risk more intelligently. That is a fundamentally different objective, and it changes what pharmaceutical companies expect from their manufacturing partners. What policymakers are pushing for, whether through the BIOSECURE Act or broader reshoring incentives, is a strategic allocation of manufacturing risk, and that is entirely rational.For LMS, this environment plays to our strengths. We have never positioned ourselves as a low-cost volume provider. Our competitive case is built on technical capability, regulatory reliability, and the ability to manage genuinely complex chemistry programs. Those attributes matter most to customers re-evaluating their supply relationships. Our investments in HPAPI containment, peptide building blocks, and integrated CDMO infrastructure reflect a deliberate commitment to being relevant precisely where complexity is highest. That is where we see sustained and growing demand, irrespective of how supply chain policy continues to evolve.How do you see the pharmaceutical landscape evolving over the next five years? How is LMS positioning itself to stay ahead of these changes?Five years from now, the defining feature of this industry will be the sheer scientific complexity embedded in pharmaceutical pipelines. Peptides, targeted oncology compounds, radiopharmaceuticals, these are not molecules you manufacture through conventional means. They demand deep process chemistry, specialized infrastructure, and partners who can genuinely co-develop solutions rather than simply execute a manufacturing order.That shift is changing how innovation-driven companies select their CDMO partners. Technical depth, regulatory track record, and the ability to navigate development risk have moved to the top of the evaluation criteria. At LMS, everything we are building right from our integrated CDMO block at Dabhasa to our HPAPI infrastructure at Vizag is calibrated to this reality. We are positioning to be a partner of choice and not just a transactional service provider.Could you provide an update on LMS’ oncology (HPAPI) manufacturing block in Visakhapatnam? How is it contributing to your CDMO strategy?Oncology manufacturing is one of the most technically exciting segments in the industry, and that complexity is only intensifying. As targeted therapies and antibody drug conjugates advance through pipelines, the demand for high-potency API capability delivered reliably, at global safety standards continues to grow.Our Vizag facility has been designed with that reality in mind, and that goes beyond containment engineering. It incorporates the process discipline, safety culture, and quality systems that high-potency manufacturing demands at every level of the organization. You cannot retrofit this kind of capability; it has to be purpose-built. What we have put in place is a platform that supports programs from early clinical development through commercial supply offering customers the continuity they need without transferring between sites as their programs mature. That continuity is a genuine competitive advantage.In December, LMS signed a strategic alliance with PolyPeptide Group AG to scale the global peptide supply chain. How will this collaboration strengthen your CDMO capabilities in the fast-growing peptide therapeutics segment?The rapid growth of peptide therapeutics, especially GLP1s, has fundamentally changed how the industry thinks about scale, reliability, and supply security. What was once a niche capability has become a core requirement, and customers are now looking for partners who can support the peptide value chain end-to-end, at a global scale.LMS’s strategy is built around serving the entire peptide market and establishing a globally competitive platform over the next three to five years, rooted in India, positioning itself as a credible partner amidst the China+1 strategy, capable of supporting both innovators and large pharmaceutical companies. The strategic alliance with PolyPeptide Group fits naturally within this vision allowing us to complement our own capabilities with additional synthesis depth and geographic flexibility, particularly for customers seeking resilient, diversified supply chains.LMS brings deep process chemistry expertise, a growing peptide intermediates and building blocks platform at Dabhasa, and strong regulatory execution. Importantly, as part of the Lupin group, we are also able to offer downstream drug product manufacturing capabilities spanning oral formulations as well as sterile injectables, including vials and drug-device delivery systems, which are increasingly critical as peptide programs move rapidly from development to commercial scale.Together, this integrated approach allows us to support customers across the full lifecycle, from peptide intermediates and APIs through to finished dosage forms. In a market defined by speed, scale, and supply assurance, this breadth of capability positions LMS to emerge as one of the leading global players in peptide CDMO services.As the industry convenes at DCAT Week, what is LMS bringing to the table this year?This year is about laying the foundations for LMS’s next phase of growth, particularly in complex and high value modalities. Strategically, our focus is on building the capabilities required to support emerging oncology and peptide adjacent platforms, while preparing for commercial scale-up over the next 18-24 months.On the technology side, LMS already has strong R&D capabilities across peptides, payloads and linkers, bioconjugation, and high potent compounds. These capabilities allow us to engage with customers early in development, solve complex chemistry challenges, and support rapid transition from discovery into development programs. Building on this base, we are progressing plans to establish commercial-scale GMP capacities in payload-linker synthesis and bioconjugation, including the development of a dedicated GMP facility in Vizag. This is a critical step for us as more antibody drug conjugates and related platforms move toward late-stage development and commercialization.Equally important is how we engage with customers. Alongside traditional CDMO models, we are increasingly offering alternative business models such as dedicated facilities, long-term capacity commitments, and guaranteed supply arrangements designed to address customers’ growing concerns around security, scalability, and speed to market. Overall, the year ahead is about execution including strengthening our R&D engine, advancing commercial-scale infrastructure, and deepening customer partnerships so that LMS is well positioned to support complex programs as they move into clinical and commercial reality.LMS has articulated its ambition to emerge as a trusted global CDMO partner with next-generation manufacturing capabilities and scientific agility. How would you assess your progress toward that goal?Trusted partnerships are earned over time, and I am clear-eyed about that. What I can say with confidence is that the strategic choices we have made over the past year have been the right ones, and the investment portfolio we have assembled aligns with direction the industry is heading.The development of our integrated CDMO block at Dabhasa, the scaling of peptide building blocks capabilities, the Vizag HPAPI facility, the PolyPeptide alliance, these reflect a coherent long-term strategy. What continues to occupy my attention most is execution. Infrastructure sets the stage, but it is our science, our quality systems, and our people that customers will ultimately judge us by. That work is ongoing, and it is where I spend most of my time.Could you update us on LMS’ green manufacturing initiatives? How is sustainability being integrated into your operations and facilities?Sustainability has shifted from a compliance requirement to a genuine competitive dimension, and I think that shift is permanent. Customers, investors, and regulators are asking harder questions, and organizations treating it just as a reporting exercise will find themselves at a disadvantage.Our approach remains grounded in the belief that durable environmental improvement comes from process intelligence. When you optimize synthesis routes for atom economy, reduce solvent intensity, and engineer waste out at the design stage, you improve sustainability and manufacturing economics simultaneously. These are not competing priorities. We are embedding green chemistry principles across our development workflows and investing in solvent recovery and waste management infrastructure. Our parent organization Lupin Limited was recently recognized among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA) attaining an overall score of 91 out of 100 establishing itself as the leading pharmaceutical company globally, and the leader across all sectors in India, surpassing both Indian and international peers which underscores our commitment.

Impressions: 2299

VLOG #PharmaReel

[Sponsored by another company]

Innovative Solution Provider

This PharmaReel highlights Bloomage Biotechnology as an innovative solutions provider in bioactive materials, specializing in Sodium Hyaluronate and Hyaluronic Acid. The company is backed by active USDMFs, CEP, JDMF, and KDMF filings, offers over 200 product specifications, operates FDA-inspected, GMP-certified manufacturing facilities, and supplies customers across more than 70 countries.

Impressions: 1429

DATA COMPILATION #PharmaFlow

[Sponsored by another company]

CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.

Impressions: 1441

Contact Smilax Laboratories Limited and get a quotation

Smilax Laboratories Limited is a supplier offers 62 products (APIs, Excipients or Intermediates).

Find Escitalopram Oxalate bulk with CEP, WC offered by Smilax Laboratories Limited

Find Esomeprazole Magnesium bulk with CEP, WC offered by Smilax Laboratories Limited

Find Guaifenesin bulk with CEP, WC offered by Smilax Laboratories Limited

Find Omeprazole bulk with CEP, WC offered by Smilax Laboratories Limited

Find Sildenafil Citrate bulk with CEP, WC offered by Smilax Laboratories Limited

Find Pantoprazole Sodium bulk with CEP offered by Smilax Laboratories Limited

Find Candesartan Cilexetil bulk with CEP offered by Smilax Laboratories Limited

Find Cloperastine bulk with JDMF offered by Smilax Laboratories Limited

Find Lansoprazole bulk with WC offered by Smilax Laboratories Limited

Find Methocarbamol bulk with WC offered by Smilax Laboratories Limited

Find Norfloxacin bulk with WC offered by Smilax Laboratories Limited

Find Repaglinide bulk with WC offered by Smilax Laboratories Limited

Find Valsartan bulk with CEP offered by Smilax Laboratories Limited

Find (R)-5-CYCLOPENTYLPYRAZOLIDIN-3-ONE (RXP-II) bulk with DMF offered by Smilax Laboratories Limited

Find SLX-193 bulk with JDMF offered by Smilax Laboratories Limited

Find Pantoprazole Sodium bulk offered by Smilax Laboratories Limited

Find Amlodipine Besylate bulk offered by Smilax Laboratories Limited

Find Apixaban bulk offered by Smilax Laboratories Limited

Find Atomoxetine bulk offered by Smilax Laboratories Limited

Find Azilsartan Medoxomil Potassium bulk offered by Smilax Laboratories Limited

Find Blonanserin bulk offered by Smilax Laboratories Limited

Find Citalopram Hydrobromide bulk offered by Smilax Laboratories Limited

Find Clopidogrel bulk offered by Smilax Laboratories Limited

Find Clozapine bulk offered by Smilax Laboratories Limited

Find Dabigatran Etexilate Mesylate bulk offered by Smilax Laboratories Limited

Find Dapagliflozin bulk offered by Smilax Laboratories Limited

Find Dexlansoprazole bulk offered by Smilax Laboratories Limited

Find Duloxetine Hydrochloride bulk offered by Smilax Laboratories Limited

Find Empagliflozin bulk offered by Smilax Laboratories Limited

Find Esomeprazole Sodium bulk offered by Smilax Laboratories Limited

Find Fluoxetine Hydrochloride bulk offered by Smilax Laboratories Limited

Find Gabapentin bulk offered by Smilax Laboratories Limited

Find Ipragliflozin bulk offered by Smilax Laboratories Limited

Find Irbesartan bulk offered by Smilax Laboratories Limited

Find Itraconazole bulk offered by Smilax Laboratories Limited

Find Ivacaftor bulk offered by Smilax Laboratories Limited

Find Levocetirizine Dihydrochloride bulk offered by Smilax Laboratories Limited

Find Linagliptin bulk offered by Smilax Laboratories Limited

Find Losartan Potassium bulk offered by Smilax Laboratories Limited

Find Memantine Hydrochloride bulk offered by Smilax Laboratories Limited

Find Mirabegron bulk offered by Smilax Laboratories Limited

Find Olanzapine bulk offered by Smilax Laboratories Limited

Find Olmesartan Medoxomil bulk offered by Smilax Laboratories Limited

Find Paliperidone Palmitate bulk offered by Smilax Laboratories Limited

Find Pentoxiverine citrate bulk offered by Smilax Laboratories Limited

Find Pioglitazone Hydrochloride bulk offered by Smilax Laboratories Limited

Find Posaconazole bulk offered by Smilax Laboratories Limited

Find Prasugrel bulk offered by Smilax Laboratories Limited

Find Ranolazine bulk offered by Smilax Laboratories Limited

Find Risperidone bulk offered by Smilax Laboratories Limited

Find Rivaroxaban bulk offered by Smilax Laboratories Limited

Find Sacubitril-Valsartan bulk offered by Smilax Laboratories Limited

Find Saxagliptin bulk offered by Smilax Laboratories Limited

Find Sumatriptan bulk offered by Smilax Laboratories Limited

Find Tadalafil bulk offered by Smilax Laboratories Limited

Find Tamsulosin bulk offered by Smilax Laboratories Limited

Find Telmisartan bulk offered by Smilax Laboratories Limited

Find Ticagrelor bulk offered by Smilax Laboratories Limited

Find Tolvaptan bulk offered by Smilax Laboratories Limited

Find Vildagliptin bulk offered by Smilax Laboratories Limited

Find Vonoprazan Fumarate bulk offered by Smilax Laboratories Limited

Find Vortioxetine Hydrobromide bulk offered by Smilax Laboratories Limited

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.